Arbutus to Report Fourth Quarter and Year End 2022
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-16, 19:44
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-01-27, 19:32
Arbutus Announces Resignation of Board Member
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
